Trends in utilization of bariatric surgery, 2009–2012

Nguyen, Ninh T.; Vu, Stephen; Kim, Eric; Bodunova, N. A.; Phelan, Michael

doi:10.1007/s00464-015-4535-9

Cited by 87 publications

(58 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Keywords Endoscopic stent Á Anastomotic leak Á Esophageal leak Á Self-expandable metal stent Á Leak management Á Bariatric surgery Surgical therapy for obesity as well as both esophageal and gastric malignancy is commonly performed procedures worldwide [1][2][3][4]. While there have been improvements in clinical outcomes in recent years, anastomotic and stapleline leaks remain a potentially deadly complication of foregut surgery associated with significant morbidity and mortality and have been reported at rates up to 10 % of the time [5][6][7][8][9][10].…”

Section: Introductionmentioning

confidence: 98%

Efficacy of endoscopic management of leak after foregut surgery with endoscopic covered self-expanding metal stents (SEMS)

et al. 2016

View full text Add to dashboard Cite

SEMS are effective tools for the management of leaks after foregut surgery. The biggest challenge with this approach is stent migration. Caution is warranted due to the risk of fatal complications such as aorto-esophageal fistula formation. No type of surgery or particular patient factor, including age, sex, BMI, albumin, history of radiation, malignancy, and comorbid diabetes or coronary artery disease, appeared to be correlated with success rate. Larger studies are needed to determine factors predictive of clinical success.

show abstract

Section: Introductionmentioning

confidence: 98%

Efficacy of endoscopic management of leak after foregut surgery with endoscopic covered self-expanding metal stents (SEMS)

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Recent data from the United States National Inpatient Sample has shown that in-hospital mortality has dropped from 0.8 % in 1998 to 0.07 % in 2012 [2]. We recently reported that in-hospital mortality after bariatric surgery in France was as low as 0.038 % in 2014 [1].…”

mentioning

confidence: 94%

“…First, the volume of surgery has increased substantially during the past decade, and volume has been shown to be a major predictor of outcome. In a study examining the relationship between hospital volume and outcomes in bariatric surgery, Nguyen and colleagues reported that the observed mortality was considerably lower at high-volume compared with low-volume hospitals (0.3 vs 1.2 %, respectively) [2]. Second, innovations in bariatric surgical techniques lead to better preparation and selection of patients.…”

mentioning

confidence: 97%

Postoperative Mortality After Bariatric Surgery: Do the Numbers Reflect the Reality?

et al. 2016

View full text Add to dashboard Cite

“…Dietary and lifestyle modifications are unlikely to maintain significant long-term weight loss in the majority of patients 4. Bariatric surgery, which was performed in 47 per 100,000 adults in 2012, is the most successful treatment for individual patients, but has had limited effect on obesity at the population level due to its less utilization 5. There are multiple reasons for the low number of people opting for bariatric surgery, including invasiveness, cost, risk, food limitations, and access.…”

Section: Introductionmentioning

confidence: 99%

The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy

Kumar¹,

Sullivan²,

Thompson³

2017

DMSO

View full text Add to dashboard Cite

Weight management is increasingly incorporating endoscopic bariatric therapy (EBT). As the global burden of obesity and its comorbidities has increased, it is evident that novel therapeutic approaches will be necessary to address the obesity epidemic. EBTs offer greater efficacy than diet and lifestyle modification and lower invasiveness than bariatric surgery. The US Food and Drug Administration has approved two intragastric balloons and aspiration therapy for the treatment of obesity: Apollo Orbera is indicated for the treatment of Class I and Class II obesity, Re Shape Integrated Dual Balloon system is indicated for the same range with a comorbidity, and Aspire Bariatrics AspireAssist is approved for patients with a body mass index of 35–55 kg/m2. These devices have proven safe and effective in clinical trials and are gaining commercial acceptance in the USA; the Orbera has been used extensively outside the USA for over 20 years. These devices will need to be delivered in the context of a multidisciplinary weight loss program, integrating comprehensive care of obesity. Patient selection is important, and ensuring appropriate patient expectations and understanding of alternatives such as pharmacologic therapy and surgery is essential. With several EBTs on the horizon, patients with obesity will have an even broader array of safe and effective options for weight management in the future.

show abstract

Trends in utilization of bariatric surgery, 2009–2012

Abstract: In the USA, the annual volume of inpatient bariatric surgery continues to be stable. Utilization of the laparoscopic approach to bariatric surgery remains high, while the in-hospital mortality continues to be low at ≤0.10 % throughout the 4-year period.

Cited by 87 publications

References 6 publications

Efficacy of endoscopic management of leak after foregut surgery with endoscopic covered self-expanding metal stents (SEMS)

Efficacy of endoscopic management of leak after foregut surgery with endoscopic covered self-expanding metal stents (SEMS)

Postoperative Mortality After Bariatric Surgery: Do the Numbers Reflect the Reality?

The role of endoscopic therapy in obesity management: intragastric balloons and aspiration therapy

Contact Info

Product

Resources

About